$AMGN Headlines Nasdaq breaks out, reaches less-charted

New Post Public Reply Private Reply Replies (0) Message Board

Aug 29, 2014 at 11:32 AM

$AMGN Headlines

Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch
Amgen plans to cut up to 2,900 jobs 9:04 p.m. July 29, 2014 - MarketWatch.com
Twitter soars 33% in after hours as results surprise on upside 4:56 p.m. July 29, 2014 - Sue Chang

What Makes OncoMed Pharmaceuticals (OMED) a Strong Sell? - Tale of the Tape 8:28 a.m. Today - Zacks.com
Today's Market: Red Hot Biotech And Big Pharma Names To Watch 8:22 a.m. Today - Seeking Alpha
Amgen's Chronic Heart Failure Drug Gets Priority Review - Analyst Blog 6:20 p.m. Aug. 28, 2014 - Zacks.com
Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang - Analyst Blog 5:50 p.m. Aug. 28, 2014 - Zacks.com
MediciNova Rises on FDA's Nod on MN-166 Study Initiation - Analyst Blog 5:00 p.m. Aug. 28, 2014 - Zacks.com
BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog 4:35 p.m. Aug. 28, 2014 - Zacks.com
Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog 4:30 p.m. Aug. 28, 2014 - Zacks.com
Amgen cholesterol-lowering therapeutic candidate succeeds in Phase 3 trial 10:09 a.m. Aug. 28, 2014 - Seeking Alpha
Stocks Hitting 52-Week Highs 9:19 a.m. Aug. 28, 2014 - benzinga.com
After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? 2:06 p.m. Aug. 27, 2014 - GuruFocus.com
Return To Behemoth Stocks 10:25 a.m. Aug. 27, 2014 - Seeking Alpha
Amgen Heart Drug Gets FDA Priority 10:12 a.m. Aug. 27, 2014 - The Wall Street Journal Interactive Edition
Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog 9:49 a.m. Aug. 27, 2014 - Zacks.com
Why Amgen Stock Is A Long-Term Investment Opportunity 9:48 a.m. Aug. 27, 2014 - Seeking Alpha
Rising Short Interest in Biotech Stocks 9:42 a.m. Aug. 27, 2014 - 247WallSt.com
Ivabradine gets priority review 9:41 a.m. Aug. 27, 2014 - Seeking Alpha
Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog 6:44 p.m. Aug. 26, 2014 - Zacks.com
Drug Maker in High-Stakes Race With Rivals 6:06 p.m. Aug. 26, 2014 - The Wall Street Journal Interactive Edition
Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog 5:20 p.m. Aug. 26, 2014 - Zacks.com
HCP Boosts Of 29 Years Of Dividend Increases 4:27 p.m. Aug. 26, 2014 - Investors Business Daily

Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic 9:30 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol 9:15 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9:00 a.m. Aug. 28, 2014 - PR Newswire - PRF
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 9:15 a.m. Aug. 27, 2014 - PR Newswire - PRF
Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 4:55 p.m. Aug. 26, 2014 - PR Newswire - PRF
Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell 4:15 p.m. Aug. 25, 2014 - PR Newswire - PRF
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck 9:20 a.m. Aug. 20, 2014 - PR Newswire - PRF
A New Cannabinoid-based Arthritis Therapy in the Making 9:50 a.m. Aug. 19, 2014 - ACCESSWIRE
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 1:55 a.m. Aug. 19, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis 5:17 p.m. Aug. 18, 2014 - PR Newswire - PRF
Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance Solidifies Company's Insolvency, Substantially Raises Specter of Bankruptcy 9:15 a.m. Aug. 14, 2014 - PR Newswire - PRF
Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates 4:12 p.m. Aug. 13, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma 4:01 p.m. Aug. 13, 2014 - PR Newswire - PRF
Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs 1:07 p.m. Aug. 11, 2014 - PR Newswire - PRF
Amgen Receives CEO Cancer Gold Standard Accreditation 7:00 a.m. Aug. 11, 2014 - BusinessWire - BZX
Critical Alerts For Stratasys, Horizon Pharma, Isis Pharmaceuticals, Amgen, and Discover Financial Services Released By InvestorsObserver 9:31 a.m. Aug. 8, 2014 - PR Newswire - PRF
Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth 9:13 a.m. Aug. 5, 2014 - PR Newswire - PRF
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 11:55 a.m. Aug. 4, 2014 - PR Newswire - PRF
Earnings Headlines - Amgen 9:30 a.m. Aug. 4, 2014 - PR Newswire - PRF
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Skandia's Soundproofing Kit Expands to Brazil's Skies

Soundproofing Takes Off in Brazil Skandia has just pulled off a neat trick, earning the nod from Brazil's National Civil Aviation Agency (ANAC) for their King Air soundproofing kit. That means quieter skies ahead for operators of the King Air 200 and 300 series in Brazil. This is no small feat, folks; it's like finally getting that coveted backstage pass after years of...

NYSE Texas Redefines the U.S. Capital Markets Landscape

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...

ROKFORM’s Signal Card: A Wallet Tracker for All

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Charter Next Generation Unveils Gen 2 MDO-PE Films

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Northern Jet Names Veteran Matthew Harris as CEO

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Community Banks Missing $106B Lending Opportunity?

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Bob Evans' Protein Mac & Cheese: Practical Power Play

Has anyone else noticed just how fast the world spins when it comes to consumer trends these days? Bob Evans is hopping right on the protein bandwagon with its latest launch, a microwave-ready Protein Macaroni & Cheese that packs 18 grams of protein per serving. You gotta hand it to them for seizing opportunity when they see it. This one's not just about tossing a new...

Cala Launches Game-Changer Wearable for Tremor Relief

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Purina Institute Highlights Nutritional Science at WSAVA 2026

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...